The de-SPAC provides a strong cash runway (~$332.6M) to fund commercialization of the SimpleScreen CRC test pending FDA approval. The positive clinical data and $70M Abbott milestone are key catalysts. Monitor the FDA review timeline and any supplemental PMA submission for the next-gen test, as well as potential selling pressure from the ~60.9% of shares subject to registration rights after the 6-month lock-up expires.
Price Chart
Executive Summary
Freenome completed its business combination with SPAC Perceptive Capital Solutions Corp (PCSC), becoming a publicly traded company on Nasdaq under ticker FRNM. The de-SPAC transaction included a $240M PIPE at $10/share and conversion of a Roche convertible note, providing gross proceeds of ~$310.3M. The filing also confirms the change of control, new board and management, adoption of equity plans, and a change in auditor to Ernst & Young, with the combined entity now holding ~$332.6M in cash to fund its colorectal cancer screening commercialization.
Key Financial Metrics
Key Facts
- Freenome completed its business combination with PCSC, becoming a publicly traded company on Nasdaq under ticker FRNM.
- Gross proceeds of approximately $310.3 million were received, including $240 million from a PIPE at $10.00 per share and $70.3 million from PCSC's trust account.
- The combined company has pro forma cash and cash equivalents of approximately $332.6 million as of March 31, 2026.
- Freenome equity holders own ~63.4% of the combined entity, PIPE investors ~22.3%, and Roche (via convertible note conversion) ~6.0%.
- The company's SimpleScreen CRC test met all primary and secondary endpoints in a pivotal study, with a $70 million milestone payment from Abbott pending FDA approval.
- The board of directors was reconstituted with seven members, and Aaron Elliott remains CEO.
- WithumSmith+Brown was dismissed as auditor, and Ernst & Young was appointed as the new independent registered public accounting firm.
- Approximately 65.4 million shares (~60.9% of total outstanding) are subject to registration rights for resale.
Financial Impact
Gross proceeds of ~$310.3M from the business combination, including $240M PIPE and $70.3M from trust. Pro forma cash of ~$332.6M. Historical revenue was $30.4M (FY2025) and $4.2M (Q1 2026), with net losses of $263.1M and $65.3M respectively.
Risk Factors
- FDA approval for SimpleScreen CRC is not yet secured; any delay or denial would severely impact the business plan.
- The company is pre-revenue from its core product and has a history of significant operating losses ($263M in FY2025).
- Approximately 60.9% of shares are subject to registration rights, creating potential overhang and selling pressure after lock-up expiration.
- Dependence on the Abbott commercial collaboration and technology transfer for market launch.
- High cash burn rate from R&D and commercialization efforts could require additional financing.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-029471 |
| Document: ef20078324_8k.htm | 0001140361-26-029471 |
| Document: ef20078324_ex10-15.htm | 0001140361-26-029471 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $14.06 $14.01 | ▼ −0.36% | ▼ −0.88% | $12.72 (−9.53%) |
Oct 15, 2026 11d ago | Press Release | $11.75 $12.57 | ▲ +6.98% | ▲ +6.56% | $12.72 (+8.26%) |
Aug 28, 2026 8w ago | EFFECT | $14.79 $14.79 | · 0.00% | ▲ +0.30% | $12.72 (−14.00%) |
Aug 18, 2026 9w ago | S-1 | $13.63 $13.51 | ▼ −0.88% | ▼ −0.04% | $12.72 (−6.68%) |
Jul 27, 2026 12w ago | 3 | $10.77 $10.06 | ▼ −6.59% | ▼ −5.05% | $12.72 (+18.11%) |
Jul 23, 2026 13w ago | 8-K | $11.24 $11.38 | ▲ +1.25% | ▲ +1.22% | $12.72 (+13.17%) |
Jul 20, 2026 14w ago | Press Release | $13.01 $13.14 | ▲ +1.00% | ▲ +1.12% | $12.72 (−2.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers